Tadalafil
- Generic Name
- Tadalafil
- Brand Names
- Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N3O4
- CAS Number
- 171596-29-5
- Unique Ingredient Identifier
- 742SXX0ICT
- Background
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity fo...
- Indication
Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 7
- Registration Number
- NCT03993353
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT03785210
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2022-10-05
- Target Recruit Count
- 50
- Registration Number
- NCT03238365
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT03166787
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Actelion
- Target Recruit Count
- 46
- Registration Number
- NCT02968901
- Locations
- 🇫🇷
Hôpital de Haut Levêque, Bordeaux, France
🇫🇷CHU Site du Bocage, Dijon, France
🇫🇷Hôpital Louis Pradel, Lyon, France
Effect of Tadalafil on Erectile Dysfunction Treatment and QOL Improvement Effect (by SF-12) in Andropause Patients With Erectile Dysfunction
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 40
- Registration Number
- NCT02943356
- Locations
- 🇰🇷
Uijeongbu St.Mary's Hospital, Gyeonggi-do, Korea, Republic of
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 225
- Registration Number
- NCT02891850
A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Yuyu Pharma, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02839122
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 141
- Registration Number
- NCT02819440
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Effect of Tadalafil on Cerebral Large Arteries in Stroke
- Conditions
- Interventions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Christina Kruuse
- Target Recruit Count
- 20
- Registration Number
- NCT02801032
- Locations
- 🇩🇰
Department of Neurology, Herlev-Gentofte Hospital, Herlev, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.